By Gina Shaw
Originally published by our sister publication, Specialty Pharmacy Continuum
For well over a year, pharmacists, physicians and patients have been anticipating the possibility of a shortage of immune globulin (IG) products, as the COVID-19 pandemic led to a significant decline in donations of the blood plasma that is the primary component of these therapies.